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Abstract
Organ preservation and ischemia reperfusion injury as-
sociated with liver transplantation play an important 
role in the induction of graft injury. One of the earliest 
events associated with the reperfusion injury is en-
dothelial cell dysfunction. It is generally accepted that 
endothelial nitric oxide synthase (e-NOS) is cell-pro-
tective by mediating vasodilatation, whereas inducible 
nitric oxide synthase mediates liver graft injury after 
transplantation. We conducted a critical review of the 
literature evaluating the potential applications of regu-
lating and promoting e-NOS activity in liver preservation 
and transplantation, showing the most current evidence 
to support the concept that enhanced bioavailability of 
NO derived from e-NOS is detrimental to ameliorate 
graft liver preservation, as well as preventing subse-
quent graft reperfusion injury. This review deals mainly 
with the beneficial effects of promoting “endogenous” 
pathways for NO generation, via  e-NOS inducer drugs 
in cold preservation solution, surgical strategies such as 
ischemic preconditioning, and alternative “exogenous” 
pathways that focus on the enrichment of cold storage 
liquid with NO donors. Finally, we also provide a basic 
bench-to-bed side summary of the liver physiology and 
cell signalling mechanisms that account for explaining 
the e-NOS protective effects in liver preservation and 
transplantation.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Ischemia-reperfusion (IR) injury during liver transplanta-
tion (LT) is a complex, multi-factorial process in which 
numerous mediators and a variety of  cells interact, lead-
ing to tissue damage. It is one of  the major cause of  both 
initial poor function and primary non-function of  liver al-
lograft, and is responsible for 81% of  re-transplantations 
during the first week after surgery. An intricate network 
of  hepatic and extra-hepatic mechanisms is involved in 
the genesis of  hepatic IR[1-3].
EDITORIAL
World J Gastroenterol  2011 June 28; 17(24): 2879-2889
ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2011 Baishideng. All rights reserved.
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v17.i24.2879
2879 June 28, 2011|Volume 17|Issue 24|WJG|www.wjgnet.com
Ben Abdennebi H et al . eNOS derived NO in liver graft
Cold storage and warm reperfusion are unavoidable 
steps in transplantation and all grafts undergo some de-
gree of  IR injury. The cascade of  events involves micro-
vasculature (sinusoidal endothelial cells or SEC), Kupffer 
cells, Ito cells, parenchyma (hepatocytes) and bile ducts. 
Cold ischemia during organ storage, which is intention-
ally applied to reduce the metabolic activity of  cells in or-
der to preserve the graft before its transplantation, has a 
substantial effect on graft function. Also, warm ischemia 
that begins at implantation has an additional negative im-
pact on graft function and outcome. Whatever the type 
of  attack, liver graft damage initiated during the ischemic 
phases is exacerbated after reperfusion with oxygen and 
the reintroduction of  blood elements. 
Although our understanding of  the pathophysiology 
of  IR injury is only partial, many response elements in-
dicate that vascular endothelium disruption, the immune 
response, oxidative mediators, and several cell-death 
pathways all play important roles. A variety of  mediators 
have been implicated, including reactive oxygen species 
(ROS) and inflammatory mediators tumor necrosis factor 
(TNF)-α, interleukin (IL)-6, IL-1, transforming growth 
factor-β, interferon-γ and endotheline (ET)-1. Further-
more, complement and chemokines are also released, 
which leads to leukocyte recruitment and activation. 
Upregulated adhesion molecules, including intercellular 
adhesion molecule 1 and E-selectin, enhance endothelial-
immune cell interactions. ROS directly injure many cyto-
skeletal and functional cellular components, causing cell 
damage. After IR, direct endothelial damage and abnor-
mal vascular tone occurs as a result of  an imbalanced 
sensitivity to mediators of  vasoconstriction and vasodila-
tion, such as ET-1/nitric oxide (NO). Endothelial injury 
also causes cell swelling and narrowing of  the vascular 
lumen, further reducing blood flow. Finally, key regulators 
of  apoptosis, such as caspases, are upregulated resulting 
in increased cell death.
It is now largely appreciated that IR associated with 
LT leads to a rapid endothelial dysfunction characterized 
by a marked decrease in NO production[4-6]. The decrease 
in NO bioavailability occurs within the first few minutes 
after reperfusion, and appears to be due to decreased 
synthesis of  NO by NO synthase (NOS), enhanced in-
activation of  NO by the overproduction of  superoxide 
anion (O2-), or both. Experimental studies emphasize 
that it is essential to minimize the deregulation of  hepatic 
microcirculation during LT[7].
NO is a free-radical diatomic gas of  low molecular 
weight with an unpaired electron[8]. It is highly lipophilic, 
allowing it to permeate quickly across the cell mem-
branes. Its half-life in vivo is a few seconds, and it is rapid-
ly converted to stable nitrites (NO2-) and nitrates (NO3-)[8]. 
Endogenous NO is synthesized from the amino acid 
precursor L-arginine in an oxidation reaction, catalyzed 
by the NOS enzymes. This complex reaction requires the 
presence of  co-substrates O2 and NAD(P)H (nicotina-
mide adenine dinucleotide phosphate reduced), as well as 
many cofactors such as flavin adenine dinucleotide, flavin 
mononucleotide and BH4 (tetrahydrobiopterin)[8,9]. There 
are three isoforms of  NOS expressed in the liver in dif-
ferent cells and in different conditions, namely endothe-
lial NOS (e-NOS), neuronal NOS (n-NOS) and inducible 
NOS (i-NOS). Both e-NOS and n-NOS are constitu-
tively present in liver. The exact role of  n-NOS in the 
pathophysiology of  IR injury during LT remains to be 
established[10]. n-NOS has been observed within neurons 
innervating the portal tracts by histochemical methods, 
and several authors believe that this protein is scarcely 
expressed in the liver[11,12]. In contrast to inducible NOS, 
constitutive NOS activation requires Ca2+.
Like any important signaling molecule, NO diffuses 
freely across cell membranes. Under physiological condi-
tions, NO binds to soluble guanylate cyclase inside cells 
and then induces the production of  large quantities of  
cGMP (guanosine 5’-monophosphate), which then trig-
gers the signal (Figure 1)[13]. In vivo, NO is inactivated 
mainly by superoxide anion, but other pathways could 
be involved. The first pathway involves the autoxidation 
of  NO to NO2- and then to NO3-. Other pathways may 
be mediated by metal-catalyzed oxidation reactions. The 
copper-containing protein ceruloplasmin (P-Cu2+) has 
been shown to rapidly oxidize NO to NO2- in physiologi-
cal conditions[14,15]. In addition to the P-Cu2+-mediated 
reaction, ferrous deoxygenated hemoglobin (Hb-Fe2+O2; 
oxyhemoglobin) rapidly converts NO to NO3-.
e-NOS ACTIVITY AND e-NOS-
DERIVED NO PRODUCTION IN LT: 
PATHOPHYSIOLOGICAL ASPECTS
e-NOS is constitutively expressed in venous and arterial 
endothelial cells and it produces small quantities of  NO 
(at picomolar levels)[16]. It is the main source of  NO in 
endothelial cells under physiologic conditions[9]. e-NOS is 
also induced in response to specific extracellular stimuli, 
such as shear stress[17] and metabolic stress (Figure 1)[18]. 
e-NOS is localized to the caveolae[19,20], which are micro-
domains of  the plasma membrane that have been impli-
cated in a variety of  cellular functions, including signal 
transduction. Caveolin proteins are the major coat pro-
teins of  caveolae, and in endothelial cells e-NOS binds 
to caveolin-1. Caveolin-1 and other peptides from the 
caveola region directly inhibit e-NOS activity[21,22]. This 
complex membrane structure is sensitive to the fluid 
pressure on the membrane. 
The e-NOS activation can also be triggered through 
the signalling pathway involving serine/threonine kinase 
Akt [or protein kinase B (PKB)], which in turn is stimu-
lated by the phosphoinositide 3-kinase (PI3K)[23,24]. e-NOS 
is one of  the targets of  Akt. An important step in this 
activation is the phosphorylation by Akt of  the serine 
residue in position 1179 (bovine sequence) or serine 1177 
(human sequence) of  the e-NOS enzyme[25,26]. Therefore, 
Akt-dependent e-NOS phosphorylation may be an im-
portant mechanism in the attenuation of  IR injury after 
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LT. Treatment of  liver grafts with adenovirus encoding 
for myr-Akt improves biochemical and cytoprotective 
parameters after orthotopic LT in pigs, in comparison to 
uninfected groups[27].
Recent reports demonstrate that metabolic stress can 
elicit adenosine monophosphate protein kinase (AMPK), 
which stimulates phosphorylation of  e-NOS protein and 
increases NO bioavailability in endothelial cells[18,28,29]. The 
e-NOS-derived NO, in turn, decreases hepatic levels of  
ET-1, improves hepatic microcirculation and significantly 
attenuates TNF-α hepatic expression and, remarkably, 
reduces the activation of  caspase-8 and caspase-3 after 
OLT[30].
In addition to its key role in vascular tone regula-
tion, studies have shown that NO is involved in several 
other protective routes (Figure 2). Animal studies have 
shown that early in the reperfusion period, tissue dam-
age appears to be associated with decreased NO avail-
ability related to e-NOS down-regulation[27,31]. Similarly, 
the use of  NOS inhibitors leads to IR damage[32]. It has 
been demonstrated that e-NOS-derived NO inhibits the 
production and release of  several endothelial vasocon-
strictor factors, including ET-1[33,34]. NO also interferes 
with the adhesion and aggregation of  platelets, adhesion 
of  leukocytes and monocytes to endothelial cells in ves-
sel walls[35,36]. It also modulates the expression of  pro-
inflammatory molecules, such as vascular cell adhesion 
molecule-1 and monocyte chemoattractant protein 1. 
Furthermore, NO is emerging as an endogenous inhibi-
tor of  TNF-α. NO decreases endothelial permeability 
and also exerts anti-mitogenic effects in vascular smooth 
muscle cells by inhibiting their growth and proliferation. 
However, other lines of  evidence suggest that ROS 
production after LT reduces e-NOS activation, which 
becomes uncoupled and perturbs e-NOS-derived NO ho-
meostasis[37] (Figure 3). In parallel, i-NOS is transcription-
ally up-regulated in all liver cells, leading to the production 
of  large amounts of  NO for persistent periods[37]. Exces-
sive NO generation can be detrimental, because it may 
alter systemic vascular tone and reactivity, leading to hypo-
tension and circulatory shock[38]. In addition, the genera-
tion of  peroxynitrite (ONOO-), a potent oxidant formed 
by reacting NO with O2-[39], could also cause cell injury 
through lipid peroxidation, direct inhibition of  the mito-
chondrial respiratory chain[40,41], inhibition of  membrane 
Na+/K+ ATPase activity, or oxidative protein modification 
such as the formation of  nitrotyrosine[4,38]. Thus, NO acts 
as a double-edged sword since it has neither harmful or 
beneficial effects, depending on its source and the experi-
mental conditions. 
The importance of  e-NOS for hepatic injury after 
cold storage/warm reperfusion in transplanted liver 
grafts has been investigated. The functions of  mouse 
liver grafts retrieved from e-NOS-deficient donors and 
those from wild-type donors were compared after or-
thotopic transplantation[31]. e-NOS-deficient liver grafts 
intensified IR injury, as shown by increased ALT, necrosis 
and apoptosis, and elevated graft infiltration of  mono-
cytes/macrophages. In addition, both flow rate and sinu-
soidal diameter were diminished after transplantation of  
e-NOS-deficient grafts. All these alterations are detected 
from 4 h after LT. In another study, decreased hepatic 
bioavailability of  NO was detected as early as 1 h after 
reperfusion of  human liver transplants[4]. This decline 
was attributed to a reduction of  e-NOS protein levels af-
ter reperfusion, rather than to a change in e-NOS mRNA 
transcription. The concerned mechanism would be a rap-
id turnover/degradation of  the e-NOS enzyme[42]. The 
extent of  the alteration of  e-NOS protein expression de-
pended on the duration of  preservation, because the loss 
of  e-NOS was exacerbated after 6 h of  cold ischemia[43]. 
The stimulus for the rapid decrease in e-NOS expression 
is not known. 
LT depletes serum arginine due to a massive release of  
arginase Ⅰ from cold-injured liver parenchymal cells[44,45]. 
The depletion of  arginine decreases tissue arginine avail-
ability, with subsequent down regulation of  e-NOS[46,47]. 
In contrast, enhancement of  arginine availability through 
arginase blockade can protect against hepatic IR injury. 
The results demonstrate that inhibition of  arginase with 
nor-NOHA can partially reverse the arginine depletion 
seen in IR injury and improve the histopathological dam-
age following transplantation[48].
MODULATION OF e-NOS-DERIVED NO 
PRODUCTION FOR LT
The quality of  cold preservation is a major detriment of  
initial graft function and survival. While cold ischemia is 
considered necessary to slow tissue metabolism, it causes 
well-documented lesions in the SEC[49]. The SEC is the 
main target cell of  reperfusion injury, at least during the 
early phase[50]. Endothelial dysfunction leads to NO de-
ficiency, which has been implicated in many disorders. 
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Figure 1  Endothelial nitric oxide synthase-derived nitric oxide synthesis. 
Shear stress leads to endothelial nitric oxide synthase (e-NOS) phosphorylation 
and through pathway involving phosphoinositide 3-kinase (PI3K) and Akt. Meta-
bolic stress also phosphorylates e-NOS through the adenosine monophosphate 
kinase (AMPK) route. The coordination of signalling through these converging 
pathways allows for e-NOS activation. L-arginine is converted in the endothe-
lium monolayer by the constitutive e-NOS to nitric oxide (NO) and L-citrulline. 
NO diffuses into both the vessel lumen and the vessel wall, thereby activating 
soluble guanylate cyclase (sGC) to produce cyclic guanosine monophosphate 
(cGMP) from guanosine 5’-triphosphate (GTP). NO in concert with cGMP in-
volve tissue protection.
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The morphological changes in these cells interfere with 
the hepatic microcirculation during reperfusion (adhesion 
and activation of  platelets and leukocytes, and throm-
boses)[51]. So, improving quality of  graft preservation is 
a means to promote its immediate function, to optimize 
the allocation of  grafts and also to reduce the shortage 
of  organs. Various strategies have been developed to pro-
mote immediate recovery of  graft function and also to 
increase access to the marginal donor pool. 
Many strategies could be developed to compensate 
for the decline in NO production during LT. We can 
distinguish two ways to promote NO production in vivo: 
the endogenous and the exogenous routes (Figure 4). 
The endogenous way consists of  the use of  arginine[52] 
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nitric oxide (NO) are produced under these pathological conditions. NO, in as-
sociation with increased mitochondrial dysfunction and oxidative stress, reacts 
with superoxide anion (O2-), to produce peroxynitrite (ONOO-). Peroxynitrite, in 
concert with other oxidants, induces tissue damage.
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Figure 4  Modulation of the decline in endothelial nitric oxide synthase-
derived nitric oxide production. endothelial nitric oxide synthase (e-NOS)-
derived nitric oxide (NO) bioavailability can be compromised either by a 
reduced L-arginine and cofactor (tetrahydrobiopterin, BH4) availability, or by a 
decreased e-NOS protein activity and level. Two ways seem to be able to over-
come these obstacles: the use of exogenous sources of NO (NO donors or NO 
inhalation) and the induction of the endogenous downstream effectors of e-NOS 
(pharmacological treatment or ischemic preconditioning) or transfection by an 
adenovirus containing e-NOS enzyme. SNP: Sodium nitroprusside; GSNO: 
S-nitroso-L-glutathione; AICAR: 5-amino-4-imidazole carboxamide riboside; 
TMZ: Trimetazidine; APC: Activated protein C; AMPK: Adenosine monophos-
phate protein kinase; PI3K: Phosphoinositide 3-kinase.
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to compensate for the deficiency of  this NO precursor. 
Other methods consist of  directly influencing the activ-
ity of  the e-NOS enzyme by adding to the preservation 
solution one of  its cofactors (BH4)[53], or one of  its in-
ducers, to increase downstream effectors of  e-NOS such 
as Akt and AMPK[54-56]. Transfection of  donor liver by an 
adenovirus containing the e-NOS enzyme could also be 
envisaged before graft extraction[57,58]. Ischemic precon-
ditioning (IP) could be an endogenous source of  NO[59]. 
The exogenous route requires the use of  an exogenous 
source of  NO, which may be given directly by inhalation 
or indirectly by an NO donor such as sodium nitroprus-
side (SNP) or S-nitroso-L-glutathione (GSNO)[60-63]. 
These strategies have shown their effectiveness exper-
imentally, but are not always applicable in human clinical 
contexts. NO can react with superoxide anions to form 
ONOO-, a highly reactive oxidant, which can induce 
apoptosis and cause structural and functional disorders 
of  the graft. This explains why some authors claim that 
the contribution of  NO during cold ischemia may be un-
necessarily risky, especially if  given at a high dose[64], and 
the use of  NO in humans is controversial at present.
NO GENERATION INDUCED BY THE 
ENDOGENOUS PATHWAY
Pharmacological e-NOS induction during cold 
preservation
The potentially protective role of  endogenous NO in 
IR-induced injury to the liver is supported by recently 
published studies demonstrating enhanced hepatocellular 
injury in post-ischemic animals that had been rendered 
deficient in e-NOS[65]. In addition, researchers have dem-
onstrated that over-expression of  liver e-NOS protects 
mice from IR-induced liver injury[27,66-68]. 
Endogenous e-NOS activation and e-NOS-derived 
NO might be a promising approach to limiting organ 
injury. Several pro-survival pathways such as PI3K/Akt 
and AMPK, which are activated following hepatic injury, 
are involved in the regulation of  e-NOS. Pharmacologi-
cal up-regulation of  these pro-survival kinase cascades 
may provide an approach to limiting cold ischemic insult. 
In this regard, 5-amino-4-imidazole carboxamide ribo-
side (AICAR), carvedilol (CVD), trimetazidine (TMZ), 
activated protein C (APC) and insulin-like growth factor 
(IGF)-1 could be promising additives in preservation so-
lutions to improve the outcome of  liver grafts after cold 
storage and reperfusion. 
Recent studies have shown that the enrichment of  
University of  Wisconsin (UW) with AICAR, an activator 
of  AMPK, ameliorated long-term liver preservation[55]. 
The protective effect of  AICAR on liver injury and func-
tion seems to be mediated by enhanced e-NOS activation 
and NO generation following AMPK phosphorylation, 
which induces vasodilatation in liver grafts[55]. The rel-
evance of  AMPK as an e-NOS upstream regulator was 
evidenced by the administration of  AraA, a phospho-
AMPK inhibitor, previous to liver graft preservation, 
demonstrating that AMPK inhibition reduces e-NOS ac-
tivation and NO production[55]. In line with these results, 
Ben Mosbah et al[54] demonstrated that the use of  CVD, 
a β- and α-adrenergic blocking drug, when added to UW 
preservation solution, protected livers through the same 
mechanism[54]. Livers preserved in this solution show 
decreased transaminases levels, improved vascular resis-
tance, reduced mitochondrial damage and enhanced ATP 
levels after reperfusion. 
However, the AMPK pathway is not the only e-NOS 
modulator. Other authors have attempted to improve the 
histidine-tryptophan-ketoglutarate (HTK) preservation 
solution by supplementation with an anticoagulant and 
anti-inflammatory agent, such as APC[30]. They found that 
the modified HTK preservation solution decreased portal 
pressure and improved hepatic microcirculation through 
increased NO hepatic levels via up-regulated e-NOS. In 
addition, the solution attenuated TNF-α expression and 
markedly reduced the activation of  caspase-3 and cas-
pase-8[30]. Although the exact mechanism by which APC 
activated e-NOS remains unclear, other in vitro reports 
postulated that APC activated e-NOS via phosphati-
dylinositol 3-kinase-dependent phosphorylation, followed 
by activation of  PKB[69]. 
Recently, Institut Georges Lopez-1 (IGL-1) solution 
has been proposed as an effective alternative to UW liq-
uid in clinical kidney transplantation, and in experimental 
orthotopic LT models[70,71]. In addition, we recently dem-
onstrated that IGL-1 is more suitable than UW solution 
for fatty liver preservation and that the benefits from 
IGL-1 were linked to an increment of  NO synthesis 
through e-NOS activation which, in turn, reduced oxida-
tive stress and liver injury[72]. 
TMZ, which has been used as an anti-ischemic drug 
in the heart for over 35 years, reduced liver injury and 
improved liver regeneration and survival rate in an ex-
perimental model of  partial hepatectomy under hepatic 
blood inflow occlusion[56]. Studies examining the under-
lying protective mechanisms of  TMZ as an additive to 
UW solution for liver preservation suggest that AMPK 
up-regulation is the mechanism by which TMZ activates 
e-NOS and exerts its cytoprotective effect[55]. Another 
study demonstrated that TMZ attenuated myocardial 
IR injury via PI-3K/AKT kinase pathway activation[73]. 
We recently found that the addition of  TMZ to IGL-1 
solution has a synergistic effect on e-NOS-derived NO 
generation that favours HIF-1α accumulation during 
normothermic reperfusion[32]. Preserved HIF-1α levels 
contribute to the increase in the over-expression of  cyto-
protective proteins such as HO-1 in fatty liver grafts. 
It has been established that IGF-1 up-regulates e-NOS 
activity by interacting with a tyrosine kinase membrane 
receptor which activates the AKT signalling pathway[74,75]. 
Furthermore, trophic factors, including IGF-1, have 
been added to UW solution in an attempt to improve 
the survival of  pig orthotopic liver allografts after cold 
storage[76]. To this end, we explored the effects of  the 
addition of  IGF-1 to IGL-1 solution on fatty liver pres-
ervation during cold IRI. We examined the mechanisms 
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responsible for such effects, including AKT phosphory-
lation and NO generation. We have demonstrated that 
the beneficial action of  IGF-1 as an additive to IGL-1 is 
mediated by AKT activation and NO generation, with 
concomitant prevention of  pro-inflammatory cytokines, 
such as TNF-α[77].
Surgical e-NOS induction by IP 
IP is a technique described firstly in the heart by Murry 
et al[78] in 1986, which consists of  the application of  
short and repetitive periods of  I/R before a sustained 
one. The protective effect of  IP is not specific to the 
myocardial muscle, since it is observed in other organs 
such as skeletal muscle[79], brain[80], intestines[81], lungs[82], 
kidneys[83] and liver[34]. In any case, the protection indu-
ced by IP against IR injury seems to be specific to each 
organ and animal species, depending on the number of  
IR cycles applied before the sustained IR. For example, 
3-4 cycles are needed for the protection of  myocar-
dium[78], whereas in the liver just one cycle of  10 min 
of  ischemia and 10 min of  reperfusion is sufficient for 
maximal protection[59].
In the heart, IP offers an initial protection of  2-3 h 
after reperfusion, and a remote protection after 12-24 h 
that lasts for 2 to 3 d. A similar pattern was observed in 
the liver, although remote protection is not yet well es-
tablished. Moreover, a differential IP protection was ob-
served in the liver, also depending on the animal species. 
Molecular mechanisms responsible for hepatoprotection
The molecular basis of  IP is a sequence of  episodes trig-
gered by a rapid signal, which leads to an intracellular 
message and to the amplification of  the effector mecha-
nisms of  protection[84]. The benefits of  IP are caused by 
the release of  several inflammatory mediators such as 
adenosine and NO, which is followed by the activation 
of  multiple cellular signals. NO is generated by the ad-
enosine released (activation of  adenosine A2 receptors), 
which in turn activates the endothelial constitutive form 
of  the e-NOS enzyme[34,85], a few minutes after IP. The 
window of  liver protection induced by IP is defined by 
two factors: (1) the concentration of  adenosine must be 
high enough to induce NO; and (2) the concentration 
of  xanthine must be low enough to avoid its prejudicial 
effects. It is well established that a high concentration 
of  xanthine would support significant increases in su-
peroxide anion. This would react with NO to generate 
peroxynitrite[86], which would cancel the beneficial effects 
of  IP. Vasodilator effects of  NO release improved liver 
oxygenation and microcirculation[87], and also inhibited 
the generation of  ET, powerful vasoconstrictors gener-
ated during liver reperfusion[34]. 
In addition, IP preserves energy metabolism during 
sustained ischemia[88,89]. This is confirmed by the mainte-
nance of  ATP levels, as well as the depletion of  lactate 
accumulated during the ischemic period. This beneficial 
effect is mediated by the increase of  AMPK, whose acti-
vation can be mediated by NO[89].
The activation of  the G protein-bound A2 receptor 
by adenosine stimulates the activity of  many intracel-
lular kinases, such as protein-kinase C (PKC) and p38 
MAPK[90,91]. In addiction, recent studies implicate PKC 
in some of  the beneficial effects of  IP in liver. They 
show that PKC activation depends on the phosphoryla-
tion of  different effector molecules, such as the tyrosine 
kinases[92] and MAPK (including p38 and MAPK[93]), and 
increases the tolerance of  hepatocytes and endothelial 
cells to the ischemic insult.
Many transcription factors are involved in PKC acti-
vation, such as nuclear factor (NF)-κB, which is respon-
sible for the protective effects of  PI[94,95]. These transcrip-
tion factors modulate the expression of  particular genes, 
resulting in the synthesis of  proteins such as heat shock 
proteins (HSP), which are understood to be effectors for 
the benefits of  IP[96]. In the liver, IP is associated with 
the synthesis of  many inducible forms of  HSP: HSP70, 
HSP2 and HSP73 and heme oxygenase (HO-1/HSP32). 
The induction of  HSP depletes the binding between 
pro-inflammatory transcriptional factors and improves 
the oxidant capacity of  the cells[96-98]. Both effects could 
contribute to the decrease in TNF-α and to the attenu-
ation of  the inflammatory response of  preconditioned 
livers[99,100]. It was also suggested that IP could reduce the 
transcription of  genes, such as c-fos and c-jun, implicated 
in the development of  the hepatic IRI, and that NFκB 
activation could induce the activation of  signal translator 
and transcription activator 3, implicated in hepatoprotec-
tion and cell proliferation[89,94,96,101,102]. 
The beneficial role of  NFκB in IP is controversial. 
Whereas Funaki et al[103] demonstrate that the protective 
role of  IP is associated with the inhibition of  NFκB acti-
vation, other authors suggest the opposite, showing that 
these effects are due to NFκB activation[94,95]. These dif-
ferences could be attributed to differences in the models 
used. Besides these cellular signalization pathways, recent 
studies show that IP could induce the release of  small 
quantities of  ROSs[104] and TNF-α, contributing to the 
protective mechanisms. 
Applications to LT
Several studies in animal models have demonstrated the 
usefulness of  IP, but its application to clinical transplanta-
tion needs to be clarified. The first clinical application was 
carried out by Koneru et al[105], who used IP in deceased 
donor LT. They showed that deceased donor liver toler-
ated 5 min of  hilar clamping, but IP did not decrease graft 
injury. More recently, Azoulay et al[106] demonstrated that 
the effects of  10 min of  IP of  the liver graft in the donor 
are associated with better tolerance to ischemia, as well as 
a worsened early liver function. These studies are consis-
tent with those by Jassem et al[107], who demonstrated the 
protection of  cadaver donor livers subjected to IP prior to 
retrieval by clamping of  the hepatic pedicle for 10 min at 
24 h after transplantation. This was evidenced by a signifi-
cant decrease in transaminase levels, and a concomitant 
reduction of  the non-specific inflammatory response. 
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Similar results were obtained by Cescon et al[108], in a 
prospective randomized study on cadaver donors, by the 
use of  10 min of  IP followed by 15 min of  reperfusion. 
These authors also demonstrated a significant reduction in 
AST, ALT and i-NOS expression levels after transplanta-
tion.
Taking all this into account, new research work is 
needed to establish the “effective protection” window 
in human LT and confirm the usefulness of  IP in clini-
cal transplantation, including the marginal graft donors, 
which at present are discarded for clinical transplantation 
purposes.
NO GENERATION INDUCED BY THE “EX-
OGENOUS PATHWAY” DURING COLD 
PRESERVATION
Some considerations
Many teams have sought to improve the performance of  
storage solutions by supplementation with cytoprotective 
agents. The bulk of  the work on these specific modi-
fications was performed on cellular models in rodents. 
Unfortunately, the benefits observed were not always 
confirmed in humans and these changes have often led 
to inconclusive results in clinical practice. Several NO do-
nors have been tested experimentally for their protective 
effects on cold IR injury. However, due to the numerous 
possible reactions and related biological consequences, in-
appropriate NO levels can cause a series of  disease states. 
On the other hand, insufficient NO production also has 
serious medical consequences. NO donor therapy should 
aim to achieve the production of  the correct quantity of  
NO in the correct place for the correct length of  time. 
The exogenous NO should acts primarily as a local me-
diator to respond to specific stimuli, and then it should 
simply dissipate through diffusion and oxidation to NO2- 
and NO3-, without the need for complex catabolism. The 
chemical versatility of  NO has led to the synthesis of  a 
wide range of  NO donors, each with different modes 
and rates of  NO release. NO donors are pharmacologi-
cally active substances that spontaneously release NO (di-
rect donors) or are metabolized to NO (donors requiring 
metabolism)[109]. 
The selection of  one among these NO donors for 
therapeutic uses is not easy, since it must meet certain 
requirements. The compound must be highly soluble in 
aqueous solutions and diffuse easily into cells, where it 
produces NO. It must be a proven NO donor, remain in 
a subtoxic range, have a prolonged half-life and mimic 
the effect of  the endogenous NO. Several authors have 
amply evaluated the consequences of  the use of  NO 
donors in liver under warm ischemia conditions, but little 
work has been done on the effects on cold ischemia and 
graft preservation. In our opinion the use of  such donors 
as additive to preservation solution is limited by their 
short half-life.
Kuroki et al[110] studied the effects of  SNP on liver 
warm IR injury. They reported improvement of  liver 
microcirculation and hepatocyte injury in the early period 
of  reperfusion. In another study supporting this find-
ing, SNP infusion after a short period of  liver ischemia 
also decreased liver IR injury[111]. Interestingly, deleteri-
ous effects observed during cold storage conditions (like 
vacuolated hepatocytes, increase in intrahepatic resistance 
and diminution of  bile production) were significantly 
removed after addition of  500 mmol/L SNP to the UW 
preservation solution[60]. The authors assumed that ben-
eficial effects of  SNP were mediated by NO release[63].
In addition, GSNO has been evaluated in the liver. 
GSNO may serve as an endogenous long-lived adduct 
or carrier of  NO[112]. GSNO possesses significant anti-
platelet action at doses that cause mild hemodynamic 
effects[113]. Thus, one possible mechanism by which the 
NO-donor can protect the graft against IR-induced dam-
age could be based on its ability to block platelet aggrega-
tion, thus avoiding the intravascular coagulation that can 
occur during reperfusion. Quintana et al[60,61] evaluated the 
benefit of  the addition in UW solution of  GSNO as a 
NO donor. After assaying four GSNO concentrations (50, 
100, 250 and 500 mmol/L), they reported an improve-
ment in the properties of  UW solution when it contained 
100 mmol/L GSNO. It preserved the morphology of  
hepatocytes and endothelial cells and prevented the alter-
ation of  the hemodynamics and function of  livers after 
cold preservation/reperfusion.
Some authors conclude that nitrite (NO2-) therapy 
might prove beneficial in protecting organ function and 
integrity during periods of  IR such as those encountered 
in organ transplantation[114-116]. Under physiological condi-
tions of  pH and oxygen pressure, NO2- has been shown 
to be a non-active metabolic end product of  NO oxida-
tion with limited intrinsic biological activity[117]. How-
ever, under ischemic conditions, when e-NOS activity is 
strongly decreased as a result of  its essential dependence 
on oxygen and the depletion on arginine, an increasing 
body of  evidence indicates alternative NO production 
by NOS-independent routes. For instance, nitrite may be 
reduced back to NO by the nitrite reductase action of  de-
oxygenated hemoglobin[118], acidic disproportionation[119], 
or xanthine oxidoreductase (XOR)[120,121]. In summary, 
the use of  NO2- in the field of  cold preservation could 
be considered for the following reasons: (1) it is a highly 
stable substance with no potentially toxic effect; (2) it 
selectively releases NO under conditions that subsist in 
stored tissue, namely ischemia, hypoxia, or low pH; (3) it 
increases XOR activity, which may compensate for com-
promised constitutive e-NOS activity in terms of  NO 
production, during hypoxia and acidosis; and (4) sodium 
nitrite is an FDA-approved compound. However, the use 
of  nitrite in preservation solutions that contain allopuri-
nol (such as UW or IGL-1 solutions) would be ineffec-
tive, since this latter inhibits XOR.
NEW DIRECTIONS FOR THE FUTURE
Along these lines we have evidenced the relevance of  
e-NOS system as a useful tool for liver preservation 
Ben Abdennebi H et al . eNOS derived NO in liver graft
2886 June 28, 2011|Volume 17|Issue 24|WJG|www.wjgnet.com
against cold ischemia reperfusion injury. However, new 
potential strategies should be established in the future to 
increase e-NOS activity and modulate the NO availability, 
as well as to define the appropriate “therapeutic window” 
to provide the most suitable graft protection during cold 
storage and further during LT. A better knowledge of  
understanding the molecular pathways involved may lead 
to more efficient protective strategies to prevent early 
cold reperfusion injury during transplantation based on 
multifactorial activation of  the endogenous cytoprotec-
tive e-NOS existing in preserved liver grafts.
ACKNOWLEDGMENTS
We are grateful to Robin Rycroft at the Language Adviso-
ry Service of  the University of  Barcelona for revising the 
English text. Also Catalan Society of  Transplantation was 
acknowledged by the fellow to Mohamed Amine Zaoualí.
REFERENCES
1 Clavien PA, Harvey PR, Strasberg SM. Preservation and 
reperfusion injuries in liver allografts. An overview and syn-
thesis of current studies. Transplantation 1992; 53: 957-978
2 Casillas-Ramírez A, Mosbah IB, Ramalho F, Roselló-Catafau 
J, Peralta C. Past and future approaches to ischemia-reperfu-
sion lesion associated with liver transplantation. Life Sci 2006; 
79: 1881-1894
3 Jaeschke H. Preservation injury: mechanisms, prevention 
and consequences. J Hepatol 1996; 25: 774-780
4 Varadarajan R, Golden-Mason L, Young L, McLoughlin P, 
Nolan N, McEntee G, Traynor O, Geoghegan J, Hegarty JE, O’
Farrelly C. Nitric oxide in early ischaemia reperfusion injury 
during human orthotopic liver transplantation. Transplanta-
tion 2004; 78: 250-256
5 Tsuchiya K, Kanematsu Y, Yoshizumi M, Ohnishi H, Kirima 
K, Izawa Y, Shikishima M, Ishida T, Kondo S, Kagami S, Taki-
guchi Y, Tamaki T. Nitrite is an alternative source of NO in 
vivo. Am J Physiol Heart Circ Physiol 2005; 288: H2163-H2170
6 Kume M, Banafsche R, Yamamoto Y, Yamaoka Y, Nobiling 
R, Gebhard MM, Klar E. Dynamic changes of post-ischemic 
hepatic microcirculation improved by a pre-treatment of 
phosphodiesterase-3 inhibitor, milrinone. J Surg Res 2006; 
136: 209-218
7 Rubbo H, Darley-Usmar V, Freeman BA. Nitric oxide regu-
lation of tissue free radical injury. Chem Res Toxicol 1996; 9: 
809-820
8 Alderton WK, Cooper CE, Knowles RG. Nitric oxide syn-
thases: structure, function and inhibition. Biochem J 2001; 357: 
593-615
9 Andrew PJ, Mayer B. Enzymatic function of nitric oxide syn-
thases. Cardiovasc Res 1999; 43: 521-531
10 Shah V, Kamath PS. Nitric oxide in liver transplantation: 
pathobiology and clinical implications. Liver Transpl 2003; 9: 
1-11
11 Esteban FJ, Pedrosa JA, Jiménez A, Fernández AP, Bentura 
ML, Martínez-Murillo R, Rodrigo J, Peinado MA. Distribu-
tion of neuronal nitric oxide synthase in the rat liver. Neurosci 
Lett 1997; 226: 99-102
12 Park CS, Krishna G, Ahn MS, Kang JH, Chung WG, Kim DJ, 
Hwang HK, Lee JN, Paik SG, Cha YN. Differential and con-
stitutive expression of neuronal, inducible, and endothelial 
nitric oxide synthase mRNAs and proteins in pathologically 
normal human tissues. Nitric Oxide 2000; 4: 459-471
13 Vollmar B, Menger MD. The hepatic microcirculation: mech-
anistic contributions and therapeutic targets in liver injury 
and repair. Physiol Rev 2009; 89: 1269-1339
14 Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-
nitric oxide pathway in physiology and therapeutics. Nat Rev 
Drug Discov 2008; 7: 156-167
15 Lundberg JO, Weitzberg E. NO-synthase independent NO 
generation in mammals. Biochem Biophys Res Commun 2010; 
396: 39-45
16 Domenico R. Pharmacology of nitric oxide: molecular mech-
anisms and therapeutic strategies. Curr Pharm Des 2004; 10: 
1667-1676
17 Kolluru GK, Sinha S, Majumder S, Muley A, Siamwala JH, 
Gupta R, Chatterjee S. Shear stress promotes nitric oxide pro-
duction in endothelial cells by sub-cellular delocalization of 
eNOS: A basis for shear stress mediated angiogenesis. Nitric 
Oxide 2010; 22: 304-315
18 Bouma HR, Ketelaar ME, Yard BA, Ploeg RJ, Henning RH. 
AMP-activated protein kinase as a target for preconditioning 
in transplantation medicine. Transplantation 2010; 90: 353-358
19 García-Cardeña G, Oh P, Liu J, Schnitzer JE, Sessa WC. Tar-
geting of nitric oxide synthase to endothelial cell caveolae via 
palmitoylation: implications for nitric oxide signaling. Proc 
Natl Acad Sci USA 1996; 93: 6448-6453
20 Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, 
Ying Y, Anderson RG, Michel T. Acylation targets emdothe-
lial nitric-oxide synthase to plasmalemmal caveolae. J Biol 
Chem 1996; 271: 6518-6522
21 Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of 
endothelial nitric-oxide synthase and caveolin-1 inhibits syn-
thase activity. J Biol Chem 1997; 272: 18522-18525
22 Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation 
of endothelial nitric-oxide synthase by Ca2+-calmodulin and 
caveolin. J Biol Chem 1997; 272: 15583-15586
23 Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AK-
Tion blocks apoptosis. Cell 1997; 88: 435-437
24 Downward J. Mechanisms and consequences of activation of 
protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267
25 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, 
Zeiher AM. Activation of nitric oxide synthase in endothelial 
cells by Akt-dependent phosphorylation. Nature 1999; 399: 
601-605
26 Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh 
K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of 
endothelium-derived nitric oxide production by the protein 
kinase Akt. Nature 1999; 399: 597-601
27 Morales-Ruiz M, Fondevila C, Muñoz-Luque J, Tugues S, 
Rodríguez-Laiz G, Cejudo-Martín P, Romero JM, Navasa M, 
Fuster J, Arroyo V, Sessa WC, García-Valdecasas JC, Jiménez 
W. Gene transduction of an active mutant of akt exerts cyto-
protection and reduces graft injury after liver transplantation. 
Am J Transplant 2007; 7: 769-778
28 Chen Z, Peng IC, Sun W, Su MI, Hsu PH, Fu Y, Zhu Y, DeFea 
K, Pan S, Tsai MD, Shyy JY. AMP-activated protein kinase 
functionally phosphorylates endothelial nitric oxide synthase 
Ser633. Circ Res 2009; 104: 496-505
29 Chen Z, Peng IC, Cui X, Li YS, Chien S, Shyy JY. Shear stress, 
SIRT1, and vascular homeostasis. Proc Natl Acad Sci USA 
2010; 107: 10268-10273
30 Kuriyama N, Isaji S, Hamada T, Kishiwada M, Ohsawa I, 
Usui M, Sakurai H, Tabata M, Hayashi T, Suzuki K. The cyto-
protective effects of addition of activated protein C into pres-
ervation solution on small-for-size grafts in rats. Liver Transpl 
2010; 16: 1-11
31 Theruvath TP, Zhong Z, Currin RT, Ramshesh VK, Lemas-
ters JJ. Endothelial nitric oxide synthase protects transplanted 
mouse livers against storage/reperfusion injury: Role of 
vasodilatory and innate immunity pathways. Transplant Proc 
2006; 38: 3351-3357
32 Zaouali MA, Ben Mosbah I, Boncompagni E, Ben Abdennebi 
H, Mitjavila MT, Bartrons R, Freitas I, Rimola A, Roselló-
Catafau J. Hypoxia inducible factor-1alpha accumulation in 
Ben Abdennebi H et al . eNOS derived NO in liver graft
2887 June 28, 2011|Volume 17|Issue 24|WJG|www.wjgnet.com
steatotic liver preservation: role of nitric oxide. World J Gastro-
enterol 2010; 16: 3499-3509
33 Peralta C, Rull R, Rimola A, Deulofeu R, Roselló-Catafau J, 
Gelpí E, Rodés J. Endogenous nitric oxide and exogenous 
nitric oxide supplementation in hepatic ischemia-reperfusion 
injury in the rat. Transplantation 2001; 71: 529-536
34 Peralta C, Closa D, Hotter G, Gelpí E, Prats N, Roselló-Cata-
fau J. Liver ischemic preconditioning is mediated by the in-
hibitory action of nitric oxide on endothelin. Biochem Biophys 
Res Commun 1996; 229: 264-270
35 Taniai H, Hines IN, Bharwani S, Maloney RE, Nimura Y, Gao 
B, Flores SC, McCord JM, Grisham MB, Aw TY. Susceptibility 
of murine periportal hepatocytes to hypoxia-reoxygenation: 
role for NO and Kupffer cell-derived oxidants. Hepatology 
2004; 39: 1544-1552
36 Esch JS, Jurk K, Knoefel WT, Roeder G, Voss H, Tustas RY, 
Schmelzle M, Krieg A, Eisenberger CF, Topp S, Rogiers X, 
Fischer L, Aken HV, Kehrel BE. Platelet activation and in-
creased tissue factor expression on monocytes in reperfusion 
injury following orthotopic liver transplantation. Platelets 2010; 
21: 348-359
37 Hu M, Wang Z, Rao J, Cao Y, Jiang W, Zhang F, Li X, Wang 
X. Inhibition of inducible nitric oxide synthase worsens liver 
damage regardless of lipopolysaccharide treatment in small-
for-size liver transplantation. Transpl Immunol 2010; 23: 6-11
38 Ramalho FS, Fernandez-Monteiro I, Rosello-Catafau J, Peral-
ta C. Hepatic microcirculatory failure. Acta Cir Bras 2006; 21 
Suppl 1: 48-53
39 Szabó C. Multiple pathways of peroxynitrite cytotoxicity. 
Toxicol Lett 2003; 140-141: 105-112
40 Lacza Z, Kozlov AV, Pankotai E, Csordás A, Wolf G, Redl H, 
Kollai M, Szabó C, Busija DW, Horn TF. Mitochondria pro-
duce reactive nitrogen species via an arginine-independent 
pathway. Free Radic Res 2006; 40: 369-378
41 Lacza Z, Pankotai E, Csordás A, Gero D, Kiss L, Horváth EM, 
Kollai M, Busija DW, Szabó C. Mitochondrial NO and reac-
tive nitrogen species production: does mtNOS exist? Nitric 
Oxide 2006; 14: 162-168
42 Lang JD, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko 
BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, 
Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon 
JS, Eckhoff DE, Patel RP. Inhaled NO accelerates restoration 
of liver function in adults following orthotopic liver trans-
plantation. J Clin Invest 2007; 117: 2583-2591
43 Desrois M, Caus T, Belles PM, Dalmasso C, Lan C, Cozzone 
PJ, Bernard M. Nitric oxide pathway after long-term cold 
storage and reperfusion in a heterotopic rat heart transplanta-
tion model. Transplant Proc 2005; 37: 4553-4555
44 Roth E, Steininger R, Winkler S, Längle F, Grünberger T, 
Függer R, Mühlbacher F. L-Arginine deficiency after liver 
transplantation as an effect of arginase efflux from the graft. 
Influence on nitric oxide metabolism. Transplantation 1994; 57: 
665-669
45 Yagnik GP, Takahashi Y, Tsoulfas G, Reid K, Murase N, 
Geller DA. Blockade of the L-arginine/NO synthase pathway 
worsens hepatic apoptosis and liver transplant preservation 
injury. Hepatology 2002; 36: 573-581
46 Mori M, Gotoh T. Regulation of nitric oxide production by 
arginine metabolic enzymes. Biochem Biophys Res Commun 
2000; 275: 715-719
47 Becker T, Mevius I, de Vries DK, Schaapherder AF, zu 
Vilsendorf AM, Klempnauer J, Frölich JC, Tsikas D. The L-ar-
ginine/NO pathway in end-stage liver disease and during 
orthotopic liver and kidney transplantation: biological and 
analytical ramifications. Nitric Oxide 2009; 20: 61-67
48 Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, Shao L, 
Wu G, Murase N, Geller DA. Liver I/R injury is improved 
by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine 
(nor-NOHA). Am J Physiol Gastrointest Liver Physiol 2007; 292: 
G512-G517
49 Clavien PA. Sinusoidal endothelial cell injury during hepatic 
preservation and reperfusion. Hepatology 1998; 28: 281-285
50 Zhu J, Wang S, Bie P, Li X, Zhang Y, Xiong Y, Wang H, Ma Z, 
Li K, Dong J. Apoptosis and regeneration of sinusoidal endo-
thelial cells after extended cold preservation and transplanta-
tion of rat liver. Transplantation 2007; 84: 1483-1491
51 Lemasters JJ, Thurman RG. Reperfusion injury after liver 
preservation for transplantation. Annu Rev Pharmacol Toxicol 
1997; 37: 327-338
52 Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Wata-
nabe M, Matsuura H, Kambe M, Kajiyama G. Intravenous ad-
ministration of L-arginine inhibits angiotensin-converting en-
zyme in humans. J Clin Endocrinol Metab 1995; 80: 2198-2202
53 Yamashiro S, Kuniyoshi Y, Arakaki K, Uezu T, Miyagi K, 
Koja K. Cardioprotective effects of tetrahydrobiopterin in 
cold heart preservation after cardiac arrest. Ann Thorac Car-
diovasc Surg 2006; 12: 95-104
54 Ben Mosbah I, Roselló-Catafau J, Alfany-Fernandez I, 
Rimola A, Parellada PP, Mitjavila MT, Lojek A, Ben Abden-
nebi H, Boillot O, Rodés J, Peralta C. Addition of carvedilol 
to University Wisconsin solution improves rat steatotic and 
nonsteatotic liver preservation. Liver Transpl 2010; 16: 163-171
55 Ben Mosbah I, Massip-Salcedo M, Fernández-Monteiro I, 
Xaus C, Bartrons R, Boillot O, Roselló-Catafau J, Peralta C. 
Addition of adenosine monophosphate-activated protein ki-
nase activators to University of Wisconsin solution: a way of 
protecting rat steatotic livers. Liver Transpl 2007; 13: 410-425
56 Zaouali MA, Ben Abdennebi H, Padrissa-Altés S, Mahfoudh-
Boussaid A, Roselló-Catafau J. Pharmacological strategies 
against cold ischemia reperfusion injury. Expert Opin Pharma-
cother 2010; 11: 537-555
57 Kupatt C, Hinkel R, von Brühl ML, Pohl T, Horstkotte J, 
Raake P, El Aouni C, Thein E, Dimmeler S, Feron O, Boekste-
gers P. Endothelial nitric oxide synthase overexpression pro-
vides a functionally relevant angiogenic switch in hibernating 
pig myocardium. J Am Coll Cardiol 2007; 49: 1575-1584
58 Kaur S, Kumar TR, Uruno A, Sugawara A, Jayakumar K, 
Kartha CC. Genetic engineering with endothelial nitric oxide 
synthase improves functional properties of endothelial pro-
genitor cells from patients with coronary artery disease: an in 
vitro study. Basic Res Cardiol 2009; 104: 739-749
59 Peralta C, Hotter G, Closa D, Gelpí E, Bulbena O, Roselló-
Catafau J. Protective effect of preconditioning on the injury 
associated to hepatic ischemia-reperfusion in the rat: role of 
nitric oxide and adenosine. Hepatology 1997; 25: 934-937
60 Quintana AB, Rodriguez JV, Scandizzi AL, Guibert EE. The 
benefit of adding sodium nitroprusside (NPNa) or S-nitroso-
glutathion (GSNO) to the University of Wisconsin solution 
(UW) to prevent morphological alterations during cold pres-
ervation/reperfusion of rat livers. Ann Hepatol 2003; 2: 84-91
61 Quintana A, Rodriguez JV, Scandizzi A, Guibert EE. Effect 
of S-nitrosoglutathione (GSNO) added to the University of 
Wisconsin solution (UW): I) Morphological alteration during 
cold preservation/reperfusion of rat liver. Int J Surg Investig 
2001; 2: 401-411
62 Miki T, Subbotin V, Goller AL, Tandin A, Rao AS, Fung JJ, 
Valdivia LA. Role of UW solution and sodium nitroprusside 
in reperfusion of liver xenografts from guinea-pig to rat. Xe-
notransplantation 1999; 6: 117-122
63 Rodriguez JV, Guibert EE, Quintana A, Scandizzi A, Almada 
L. Role of sodium nitroprusside in the improvement of rat 
liver preservation in University of Wisconsin solution: A 
study in the isolated perfused liver model. J Surg Res 1999; 87: 
201-208
64 de Perrot M, Keshavjee S. Lung preservation. Semin Thorac 
Cardiovasc Surg 2004; 16: 300-308
65 Hines IN, Hoffman JM, Scheerens H, Day BJ, Harada H, 
Pavlick KP, Bharwani S, Wolf R, Gao B, Flores S, McCord JM, 
Grisham MB. Regulation of postischemic liver injury follow-
ing different durations of ischemia. Am J Physiol Gastrointest 
Ben Abdennebi H et al . eNOS derived NO in liver graft
2888 June 28, 2011|Volume 17|Issue 24|WJG|www.wjgnet.com
Liver Physiol 2003; 284: G536-G545
66 Li J, Billiar TR. Nitric Oxide. IV. Determinants of nitric ox-
ide protection and toxicity in liver. Am J Physiol 1999; 276: 
G1069-G1073
67 Kuhlencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, 
Dombkowski D, Atkinson WJ, Han F, Preffer F, Rosenzweig 
A, Sessa WC, Gimbrone MA, Ertl G, Huang PL. Role of endo-
thelial nitric oxide synthase in endothelial activation: insights 
from eNOS knockout endothelial cells. Am J Physiol Cell 
Physiol 2004; 286: C1195-C1202
68 Katsumi H, Nishikawa M, Yamashita F, Hashida M. Preven-
tion of hepatic ischemia/reperfusion injury by prolonged 
delivery of nitric oxide to the circulating blood in mice. Trans-
plantation 2008; 85: 264-269
69 Uchiba M, Okajima K, Oike Y, Ito Y, Fukudome K, Isobe H, 
Suda T. Activated protein C induces endothelial cell prolifer-
ation by mitogen-activated protein kinase activation in vitro 
and angiogenesis in vivo. Circ Res 2004; 95: 34-41
70 Ben Abdennebi H, Elrassi Z, Scoazec JY, Steghens JP, Ramel-
la-Virieux S, Boillot O. Evaluation of IGL-1 preservation solu-
tion using an orthotopic liver transplantation model. World J 
Gastroenterol 2006; 12: 5326-5330 
71 Badet L, Ben Abdennebi H, Petruzzo P, McGregor B, Espa 
M, Hadj-Aissa A, Ramella-Virieux S, Steghens JP, Portoghese 
F, Martin X. Effect of IGL-1, a new preservation solution, 
on kidney grafts (a pre-clinical study). Transpl Int 2005; 17: 
815-821
72 Ben Mosbah I, Roselló-Catafau J, Franco-Gou R, Abden-
nebi HB, Saidane D, Ramella-Virieux S, Boillot O, Peralta C. 
Preservation of steatotic livers in IGL-1 solution. Liver Transpl 
2006; 12: 1215-1223
73 Khan M, Meduru S, Mostafa M, Khan S, Hideg K, Kup-
pusamy P. Trimetazidine, administered at the onset of re-
perfusion, ameliorates myocardial dysfunction and injury by 
activation of p38 mitogen-activated protein kinase and Akt 
signaling. J Pharmacol Exp Ther 2010; 333: 421-429
74 Isenovic ER, Divald A, Milivojevic N, Grgurevic T, Fisher SE, 
Sowers JR. Interactive effects of insulin-like growth factor-1 
and beta-estradiol on endothelial nitric oxide synthase activ-
ity in rat aortic endothelial cells. Metabolism 2003; 52: 482-487
75 Isenovic ER, Meng Y, Divald A, Milivojevic N, Sowers JR. 
Role of phosphatidylinositol 3-kinase/Akt pathway in angio-
tensin II and insulin-like growth factor-1 modulation of nitric 
oxide synthase in vascular smooth muscle cells. Endocrine 
2002; 19: 287-292
76 Ambiru S, Uryuhara K, Talpe S, Dehoux JP, Jacobbi L, Mur-
phy CJ, McAnulty JF, Gianello P. Improved survival of or-
thotopic liver allograft in swine by addition of trophic factors 
to University of Wisconsin solution. Transplantation 2004; 77: 
302-319
77 Zaouali MA, Padrissa-Altés S, Ben Mosbah I, Ben Abdennebi 
H, Boillot O, Rimola A, Saidane-Mosbahi D, Roselló-Catafau J. 
Insulin like growth factor-1 increases fatty liver preservation 
in IGL-1 solution. World J Gastroenterol 2010; 16: 5693-5700
78 Murry CE, Jennings RB, Reimer KA. Preconditioning with 
ischemia: a delay of lethal cell injury in ischemic myocar-
dium. Circulation 1986; 74: 1124-1136
79 Pang CY, Yang RZ, Zhong A, Xu N, Boyd B, Forrest CR. 
Acute ischaemic preconditioning protects against skeletal 
muscle infarction in the pig. Cardiovasc Res 1995; 29: 782-788
80 Glazier SS, O’Rourke DM, Graham DI, Welsh FA. Induction 
of ischemic tolerance following brief focal ischemia in rat 
brain. J Cereb Blood Flow Metab 1994; 14: 545-553
81 Hotter G, Closa D, Prados M, Fernández-Cruz L, Prats N, 
Gelpí E, Roselló-Catafau J. Intestinal preconditioning is medi-
ated by a transient increase in nitric oxide. Biochem Biophys 
Res Commun 1996; 222: 27-32
82 Du ZY, Hicks M, Winlaw D, Spratt P, Macdonald P. Ischemic 
preconditioning enhances donor lung preservation in the rat. 
J Heart Lung Transplant 1996; 15: 1258-1267
83 Islam CF, Mathie RT, Dinneen MD, Kiely EA, Peters AM, 
Grace PA. Ischaemia-reperfusion injury in the rat kidney: the 
effect of preconditioning. Br J Urol 1997; 79: 842-847
84 Cutrn JC, Perrelli MG, Cavalieri B, Peralta C, Rosell Catafau 
J, Poli G. Microvascular dysfunction induced by reperfusion 
injury and protective effect of ischemic preconditioning. Free 
Radic Biol Med 2002; 33: 1200-1208
85 Koti RS, Seifalian AM, McBride AG, Yang W, Davidson BR. 
The relationship of hepatic tissue oxygenation with nitric 
oxide metabolism in ischemic preconditioning of the liver. 
FASEB J 2002; 16: 1654-1656
86 Peralta C, Closa D, Xaus C, Gelpí E, Roselló-Catafau J, Hotter 
G. Hepatic preconditioning in rats is defined by a balance of 
adenosine and xanthine. Hepatology 1998; 28: 768-773
87 Koti RS, Yang W, Dashwood MR, Davidson BR, Seifalian 
AM. Effect of ischemic preconditioning on hepatic microcir-
culation and function in a rat model of ischemia reperfusion 
injury. Liver Transpl 2002; 8: 1182-1191
88 Peralta C, Bartrons R, Serafin A, Blázquez C, Guzmán M, 
Prats N, Xaus C, Cutillas B, Gelpí E, Roselló-Catafau J. Ad-
enosine monophosphate-activated protein kinase mediates 
the protective effects of ischemic preconditioning on hepatic 
ischemia-reperfusion injury in the rat. Hepatology 2001; 34: 
1164-1173
89 Carrasco-Chaumel E, Roselló-Catafau J, Bartrons R, Franco-
Gou R, Xaus C, Casillas A, Gelpí E, Rodés J, Peralta C. Ad-
enosine monophosphate-activated protein kinase and nitric 
oxide in rat steatotic liver transplantation. J Hepatol 2005; 43: 
997-1006
90 Carini R, Grazia De Cesaris M, Splendore R, Domenicotti C, 
Nitti MP, Pronzato MA, Albano E. Signal pathway responsi-
ble for hepatocyte preconditioning by nitric oxide. Free Radic 
Biol Med 2003; 34: 1047-1055
91 Ricciardi R, Meyers WC, Schaffer BK, Kim RD, Shah SA, 
Wheeler SM, Donohue SE, Sheth KR, Callery MP, Chari RS. 
Protein kinase C inhibition abrogates hepatic ischemic pre-
conditioning responses. J Surg Res 2001; 97: 144-149
92 Ricciardi R, Schaffer BK, Kim RD, Shah SA, Donohue SE, 
Wheeler SM, Quarfordt SH, Callery MP, Meyers WC, Chari 
RS. Protective effects of ischemic preconditioning on the cold-
preserved liver are tyrosine kinase dependent. Transplantation 
2001; 72: 406-412
93 Carini R, De Cesaris MG, Splendore R, Vay D, Domenicotti C, 
Nitti MP, Paola D, Pronzato MA, Albano E. Signal pathway 
involved in the development of hypoxic preconditioning in 
rat hepatocytes. Hepatology 2001; 33: 131-139
94 Teoh N, Dela Pena A, Farrell G. Hepatic ischemic precondi-
tioning in mice is associated with activation of NF-kappaB, 
p38 kinase, and cell cycle entry. Hepatology 2002; 36: 94-102
95 Ricciardi R, Shah SA, Wheeler SM, Quarfordt SH, Callery 
MP, Meyers WC, Chari RS. Regulation of NFkappaB in 
hepatic ischemic preconditioning. J Am Coll Surg 2002; 195: 
319-326
96 Kume M, Yamamoto Y, Saad S, Gomi T, Kimoto S, Shimabu-
kuro T, Yagi T, Nakagami M, Takada Y, Morimoto T, Yama-
oka Y. Ischemic preconditioning of the liver in rats: implica-
tions of heat shock protein induction to increase tolerance of 
ischemia-reperfusion injury. J Lab Clin Med 1996; 128: 251-258
97 Redaelli CA, Tian YH, Schaffner T, Ledermann M, Baer HU, 
Dufour JF. Extended preservation of rat liver graft by induc-
tion of heme oxygenase-1. Hepatology 2002; 35: 1082-1092
98 Bauer M, Bauer I. Heme oxygenase-1: redox regulation and 
role in the hepatic response to oxidative stress. Antioxid Redox 
Signal 2002; 4: 749-758
99 Arai M, Thurman RG, Lemasters JJ. Ischemic preconditioning 
of rat livers against cold storage-reperfusion injury: role of 
nonparenchymal cells and the phenomenon of heterologous 
preconditioning. Liver Transpl 2001; 7: 292-299
100 Yonezawa K, Yamamoto Y, Yamamoto H, Ishikawa Y, 
Uchinami H, Taura K, Nakajima A, Yamaoka Y. Suppression 
Ben Abdennebi H et al . eNOS derived NO in liver graft
2889 June 28, 2011|Volume 17|Issue 24|WJG|www.wjgnet.com
of tumor necrosis factor-alpha production and neutrophil in-
filtration during ischemia-reperfusion injury of the liver after 
heat shock preconditioning. J Hepatol 2001; 35: 619-627
101 Carini R, Albano E. Recent insights on the mechanisms of 
liver preconditioning. Gastroenterology 2003; 125: 1480-1491
102 Ishii S, Abe T, Saito T, Tsuchiya T, Kanno H, Miyazawa M, 
Suzuki M, Motoki R, Gotoh M. Effects of preconditioning on 
ischemia/reperfusion injury of hepatocytes determined by 
immediate early gene transcription. J Hepatobiliary Pancreat 
Surg 2001; 8: 461-468
103 Funaki H, Shimizu K, Harada S, Tsuyama H, Fushida S, Tani 
T, Miwa K. Essential role for nuclear factor kappaB in isch-
emic preconditioning for ischemia-reperfusion injury of the 
mouse liver. Transplantation 2002; 74: 551-556
104 Sindram D, Rüdiger HA, Upadhya AG, Strasberg SM, Cla-
vien PA. Ischemic preconditioning protects against cold isch-
emic injury through an oxidative stress dependent mecha-
nism. J Hepatol 2002; 36: 78-84
105 Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, 
de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic 
preconditioning in deceased donor liver transplantation: a 
prospective randomized clinical trial of safety and efficacy. 
Liver Transpl 2005; 11: 196-202
106 Azoulay D, Lucidi V, Andreani P, Maggi U, Sebagh M, Ichai 
P, Lemoine A, Adam R, Castaing D. Ischemic precondition-
ing for major liver resection under vascular exclusion of the 
liver preserving the caval flow: a randomized prospective 
study. J Am Coll Surg 2006; 202: 203-211
107 Jassem W, Fuggle SV, Cerundolo L, Heaton ND, Rela M. 
Ischemic preconditioning of cadaver donor livers protects 
allografts following transplantation. Transplantation 2006; 81: 
169-174
108 Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Erco-
lani G, Varotti G, D’Errico A, Ballardini G, Pinna AD. Effect 
of ischemic preconditioning in whole liver transplantation 
from deceased donors. A pilot study. Liver Transpl 2006; 12: 
628-635
109 Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and car-
diovascular agents modulating the bioactivity of nitric oxide: 
an overview. Circ Res 2002; 90: 21-28
110 Kuroki I, Miyazaki T, Mizukami I, Matsumoto N, Matsu-
moto I. Effect of sodium nitroprusside on ischemia-reperfu-
sion injuries of the rat liver. Hepatogastroenterology 2004; 51: 
1404-1407
111 Morisue A, Wakabayashi G, Shimazu M, Tanabe M, Mukai 
M, Matsumoto K, Kawachi S, Yoshida M, Yamamoto S, Kita-
jima M. The role of nitric oxide after a short period of liver 
ischemia-reperfusion. J Surg Res 2003; 109: 101-109
112 Ghalayini IF. Nitric oxide-cyclic GMP pathway with some 
emphasis on cavernosal contractility. Int J Impot Res 2004; 16: 
459-469
113 García-Criado FJ, Rodriguez-Barca P, García-Cenador MB, 
Rivas-Elena JV, Grande MT, Lopez-Marcos JF, Mourelle M, 
López-Novoa JM. Protective effect of new nitrosothiols on the 
early inflammatory response to kidney ischemia/reperfusion 
and transplantation in rats. J Interferon Cytokine Res 2009; 29: 
441-450
114 Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, 
Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin 
MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo 
ischemia-reperfusion of the heart and liver. J Clin Invest 2005; 
115: 1232-1240
115 Lu P, Liu F, Yao Z, Wang CY, Chen DD, Tian Y, Zhang JH, 
Wu YH. Nitrite-derived nitric oxide by xanthine oxidoreduc-
tase protects the liver against ischemia-reperfusion injury. 
Hepatobiliary Pancreat Dis Int 2005; 4: 350-355
116 Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Maz-
zon E, Cuzzocrea S, Yaqoob MM, Ahluwalia A, Thiemer-
mann C. Nitrite-derived nitric oxide protects the rat kidney 
against ischemia/reperfusion injury in vivo: role for xanthine 
oxidoreductase. J Am Soc Nephrol 2007; 18: 570-580
117 Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch 
M, Kelm M. Plasma nitrite rather than nitrate reflects regional 
endothelial nitric oxide synthase activity but lacks intrinsic va-
sodilator action. Proc Natl Acad Sci USA 2001; 98: 12814-12819
118 Nagababu E, Ramasamy S, Abernethy DR, Rifkind JM. 
Active nitric oxide produced in the red cell under hypoxic 
conditions by deoxyhemoglobin-mediated nitrite reduction. J 
Biol Chem 2003; 278: 46349-46356
119 Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-
independent formation of nitric oxide in biological tissues. 
Nat Med 1995; 1: 804-809
120 Zhang Z, Naughton DP, Blake DR, Benjamin N, Stevens CR, 
Winyard PG, Symons MC, Harrison R. Human xanthine oxi-
dase converts nitrite ions into nitric oxide (NO). Biochem Soc 
Trans 1997; 25: 524S
121 Godber BL, Doel JJ, Sapkota GP, Blake DR, Stevens CR, 
Eisenthal R, Harrison R. Reduction of nitrite to nitric oxide 
catalyzed by xanthine oxidoreductase. J Biol Chem 2000; 275: 
7757-7763
S- Editor  Sun H    L- Editor  Rutherford A    E- Editor  Zheng XM
Ben Abdennebi H et al . eNOS derived NO in liver graft
